IL1RL1 and asthma: More interestingly, the results from 2 recent phase II clinical trials show that monoclonal antibodies targeting IL-33 (itepekimab) or ST2 (astegolimab) are beneficial to patients with asthma by reducing blood eosinophils, improving lung function, or lowering exacerbation rate (15, 16).